[go: up one dir, main page]

MX2016001145A - Proteina de fusion terapeutica. - Google Patents

Proteina de fusion terapeutica.

Info

Publication number
MX2016001145A
MX2016001145A MX2016001145A MX2016001145A MX2016001145A MX 2016001145 A MX2016001145 A MX 2016001145A MX 2016001145 A MX2016001145 A MX 2016001145A MX 2016001145 A MX2016001145 A MX 2016001145A MX 2016001145 A MX2016001145 A MX 2016001145A
Authority
MX
Mexico
Prior art keywords
fusion protein
therapeutic fusion
therapeutic
neprilysin
binds
Prior art date
Application number
MX2016001145A
Other languages
English (en)
Inventor
Bernd Bohrmann
Per-Ola Freskgard
Jens Niewoehner
Hendrik Knoetgen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48900891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016001145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016001145A publication Critical patent/MX2016001145A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6494—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una proteína de fusión que comprende un anticuerpo dirigido contra Aß, una entidad monovalente que se une a un receptor de la barrera hematoencefálica y una neprilisina.
MX2016001145A 2013-08-02 2014-07-30 Proteina de fusion terapeutica. MX2016001145A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13179056 2013-08-02
PCT/EP2014/066355 WO2015014884A1 (en) 2013-08-02 2014-07-30 Therapeutic fusion protein

Publications (1)

Publication Number Publication Date
MX2016001145A true MX2016001145A (es) 2016-04-29

Family

ID=48900891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001145A MX2016001145A (es) 2013-08-02 2014-07-30 Proteina de fusion terapeutica.

Country Status (20)

Country Link
US (1) US20160168253A1 (es)
EP (1) EP3027280A1 (es)
JP (1) JP2016527260A (es)
KR (1) KR20160037173A (es)
CN (1) CN105431203A (es)
AU (1) AU2014298519A1 (es)
BR (1) BR112016001782A2 (es)
CA (1) CA2919325A1 (es)
CL (1) CL2016000219A1 (es)
CR (1) CR20160041A (es)
EA (1) EA201600141A1 (es)
HK (1) HK1216159A1 (es)
IL (1) IL243353A0 (es)
MA (1) MA38797A1 (es)
MX (1) MX2016001145A (es)
PE (1) PE20160720A1 (es)
PH (1) PH12016500123A1 (es)
SG (1) SG11201600807YA (es)
WO (1) WO2015014884A1 (es)
ZA (1) ZA201600086B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EA039366B1 (ru) 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
ES2809728T3 (es) * 2015-06-24 2021-03-05 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
AU2016283344B2 (en) 2015-06-24 2022-08-04 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing BDNF
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
EP3561058B1 (en) 2016-12-26 2025-07-23 JCR Pharmaceuticals Co., Ltd. Fusion protein including bdnf
JP6956741B2 (ja) 2016-12-26 2021-11-02 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
PT3583120T (pt) 2017-02-17 2022-12-15 Denali Therapeutics Inc Polipeptídeos de ligação ao recetor de transferrina manipulados
WO2024169990A1 (zh) * 2023-02-13 2024-08-22 浙江大学绍兴研究院 双特异性抗体及其应用
WO2025180487A1 (zh) * 2024-02-29 2025-09-04 中国科学院动物研究所 嵌合多肽编程的靶向蛋白降解技术

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007040437A1 (en) * 2005-10-03 2007-04-12 Astrazeneca Ab Fusion proteins having a modulated half-life in plasma
WO2008022349A2 (en) * 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
TW200907056A (en) * 2007-03-28 2009-02-16 Astrazeneca Ab New method
WO2008135380A1 (en) * 2007-05-02 2008-11-13 F. Hoffmann-La Roche Ag Method for stabilizing a protein
US8946165B2 (en) * 2008-09-29 2015-02-03 The Regents Of The University Of California Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
WO2011160732A1 (en) * 2010-06-21 2011-12-29 Medimmune, Llc. Protease variants of human neprilysin
EA034333B1 (ru) * 2010-11-30 2020-01-29 Дженентек, Инк. Варианты антитела для переноса соединения через гематоэнцефалический барьер

Also Published As

Publication number Publication date
US20160168253A1 (en) 2016-06-16
CR20160041A (es) 2016-02-08
HK1216159A1 (zh) 2016-10-21
JP2016527260A (ja) 2016-09-08
MA38797A1 (fr) 2018-06-29
AU2014298519A1 (en) 2016-02-04
PE20160720A1 (es) 2016-07-28
PH12016500123A1 (en) 2016-04-25
WO2015014884A1 (en) 2015-02-05
CN105431203A (zh) 2016-03-23
KR20160037173A (ko) 2016-04-05
SG11201600807YA (en) 2016-03-30
IL243353A0 (en) 2016-02-29
EP3027280A1 (en) 2016-06-08
EA201600141A1 (ru) 2016-09-30
BR112016001782A2 (pt) 2017-08-29
ZA201600086B (en) 2017-04-26
CA2919325A1 (en) 2015-02-05
CL2016000219A1 (es) 2016-09-16

Similar Documents

Publication Publication Date Title
PH12016500123A1 (en) Therapeutic fusion protein
IL291073A (en) Drug conjugates of anti-egfr antibodies
IL259643A (en) Antibodies and antibody fragments for site-specific conjugation
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
IL247936A0 (en) Antibodies against egfr and drug antibody conjugates
CL2016001460A1 (es) Anticuerpo pdi-1, fragmento unificador antígeno de la misma y aplicación médica de la misma
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
CR20140585A (es) Proteinas de union a antigeno st2
TN2015000396A1 (en) Antibody drug conjugates
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
EP3250238A4 (en) Antibody drug conjugates
EP3253212A4 (en) Antibody drug conjugates
PL3004167T3 (pl) Białka wiążące antygen receptora onkostatyny m
ZA201504538B (en) Anti-lamp1 antibodies and antibody drug conjugates ,and uses thereof
GB201614162D0 (en) Antibodies, uses thereof and conjugates thereof
EP3519440A4 (en) MONOCLONAL CMET BINDERS, ACTIVE SUBSTANCE CONJUGATES AND USES THEREOF
HUE049860T2 (hu) IL-ß-t neutralizáló, humán monoklonális antitestek
LT3269735T (lt) Antikūnas prieš sklerostiną, antigeną surišantis fragmentas ir jų medicininis panaudojimas
HK40012373A (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
HK40000483A (en) Anti-egfr antibody drug conjugates